Archive for the ‘Bio-Rad Product Highlight’ Category
Professor Alec Morley, a pioneer in digital PCR, has chosen Bio-Rad Laboratories’ QX100 Droplet Digital PCR system to develop a diagnostic test for chronic myeloid leukemia (CML).
In 1992, Prof. Morley and his lab at Flinders University and Medical Center in Adelaide, South Australia, published a general method called “limiting dilution PCR” for quantifying PCR targets. As a proof of concept, they used this method for the quantification of marker mutations in acute leukemia. By diluting DNA samples so that only one or two copies per well were present and then amplifying those copies with PCR, Morley’s team was able to detect two copies of leukemic DNA against a background of 160,000 normal genomes.
They subsequently reported in The Lancet that the outcome of acute leukemia can be predicted by measuring the response to treatment using limiting dilution PCR to quantify the leukemic cells at high sensitivity. In later work, the Morley Lab used real-time quantitative PCR (qPCR) to develop a highly sensitive method for isolating and quantifying the chromosomal translocation that is typically associated with CML.
Using droplet digital PCR to diagnose leukemia
Because the translocation point for each patient is different in CML, real-time PCR conditions may vary from patient to patient and may therefore produce different results. The lab has now returned to digital PCR.
“Advancements in digital PCR have given us the ability to overcome variations in real-time PCR amplification efficiency and have also enabled us to do away with using a standard curve,” Prof. Morley said.
Monoquant, a company associated with Flinders University, recently used Bio-Rad’s QX100 system to refine the new clinical test for CML. Not only does the instrument offer high sensitivity, it also removes variability in amplification efficiency that results from using patient-specific PCR primers, a traditional sticking point for the FDA. Monoquant hopes the results from the QX100 system will fast-track the FDA approval process for its test.
“It’s a great feeling knowing that something we helped create is propelling our work today,” Prof. Morley said. “We are hoping that this new test we’re developing will offer a better degree of monitoring and better disease management for patients by tracking the progression or remission of CML.”
Bio-Rad Laboratories and Propel Labs, a biotechnology instrumentation company whose principals helped to develop the MoFlo cell sorter and the CyAn ADP Analyzer, have partnered to bring researchers the new evolution in cell sorting, the S3 cell sorter. The S3 cell sorter is an automated benchtop cell sorter that contains one to two lasers and up to four fluorescence detectors, along with forward and side scatter detectors. It uses state-of-the-art ProDrop™ technology for automation of drop delay calculation and droplet break off monitoring, thereby simplifying one of the most complex aspects of cell sorting. Without compromising performance and sensitivity, this affordable cell sorter provides exceptional sort purity and yield results. This system is ideal for sorting cells expressing fluorescent proteins like GFP or cells labeled with fluorescent markers.
The S3 cell sorter offers researchers:
- Simplified instrument setup — automated drop delay calculation and droplet break-off monitoring enable precise 1–4 color sorting with minimal training
- Reduced carryover — dual-position loading stage ensures the sample line is clean between sort runs
- Compact design — only 2.3 x 2.1 x 2.1 ft in dimension, it includes onboard fluidics and temperature control system
- Intuitive interface — user-friendly ProSort™ software for effortless instrument control and sort logic definition
The S3 cell sorter makes cell sorting easy and convenient for the most common experiments. In addition, it provides expertise and experience in cell sorting from Propel Labs along with excellent technical and service support from Bio-Rad.
MoFlo and CyAn are trademarks of Beckman Coulter Inc.